Nakamura Haruhiko, Nishimura Toshihide
Department of Chest Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.
Department of Translational Medicine Informatics, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Surg Today. 2017 Sep;47(9):1037-1059. doi: 10.1007/s00595-017-1477-y. Epub 2017 Feb 22.
Serum biomarkers provide valuable information about the diagnosis and prognosis of a wide variety of malignant tumors. Despite the identification of several useful serum biomarkers in lung cancer, consensus on their utility has not yet been reached. Furthermore, guidelines and standard protocols to implement their use for patients with lung cancer are lacking, despite the accumulation of much data on the efficacy of several serum biomarkers over recent decades. In this review, we discuss the molecular features, functions, and clinical relevance of the conventional serum biomarkers for lung cancer, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA 21-1), tissue polypeptide antigen (TPA), carbohydrate antigen 19-9 (CA19-9), sialyl Lewis (sLe), carbohydrate antigen 125 (CA-125), squamous cell carcinoma-related antigen (SCC-Ag), neuron-specific enolase (NSE), and pro-gastrin-releasing peptide (proGRP), aiming to provide a snapshot of the current landscape and their potential combined utility in the diagnosis and prognosis of lung cancer.
血清生物标志物为多种恶性肿瘤的诊断和预后提供了有价值的信息。尽管在肺癌中已鉴定出几种有用的血清生物标志物，但对于它们的实用性尚未达成共识。此外，尽管近几十年来积累了大量关于几种血清生物标志物疗效的数据，但缺乏将其用于肺癌患者的指南和标准方案。在本综述中，我们讨论了肺癌传统血清生物标志物的分子特征、功能和临床相关性，包括癌胚抗原（CEA）、细胞角蛋白19片段21-1（CYFRA 21-1）、组织多肽抗原（TPA）、糖类抗原19-9（CA19-9）、唾液酸Lewis（sLe）、糖类抗原125（CA-125）、鳞状细胞癌相关抗原（SCC-Ag）、神经元特异性烯醇化酶（NSE）和胃泌素释放肽前体（proGRP），旨在提供当前情况的概述以及它们在肺癌诊断和预后中的潜在联合效用。
